26.08.2026 • News

Wiley Launches Its First Spectral Analysis API Portfolio

New APIs extend Wiley's gold-standard spectral data and analytical intelligence directly into lab, vendor, and platform workflows.

abstract image
© Wiley

Wiley, a global leader in authoritative content and research intelligence, recently announced the launch of its spectral analysis application programming interface (API) portfolio, providing users with a new, faster way to access its trusted spectral data, analytical algorithms, and predictive models—within their own workflows.

Wiley has one of the most comprehensive and trusted collections of scientific reference databases in the world, relied upon as a gold standard for identifying unknown chemical compounds by laboratories, instrument vendors, and software platforms across pharmaceuticals, forensics, environmental science, chemicals, food, materials, and other fields. The new portfolio extends the data and tools into modern, API-driven environments—allowing users to integrate high-quality spectral intelligence directly into their own systems and workflows.

As sample volumes grow and lab workflows become more automated and software-driven, identifying and verifying compounds quickly and reliably becomes even more critical. The new API portfolio meets that need directly, giving labs and platforms a faster way to complete the process, whether catching a quality issue on a production line or identifying an unknown compound in the field. The result is less manual effort, faster analysis, and more confidence in the answer.

The launch builds on Wiley's mission to transform knowledge into actionable intelligence for corporate and academic researchers around the world.

"Speed matters when you're trying to identify an unknown substance; a delayed analysis can mean an assembly line sitting idle or a forensic lab holding up a case,” said Armughan Rafat, Wiley senior vice president and chief AI and data services officer. “We've spent decades building the reference data this industry trusts. Now, by making that spectral data and analytical intelligence available through APIs, we're setting the standard for how labs and vendors turn unknowns into answers faster and at scale."

The API portfolio launches with four core capabilities:

  • Spectral Database Search API – Query Wiley’s comprehensive reference collections for rapid compound identification.
  • Spectrum-Structure Validation API – Confirm proposed chemical structures against experimental spectral data.
  • Compound Classification API – Classify unknown substances, including drugs, based on compound class.
  • Spectra Prediction API – Generate predicted spectra to support research, method development, and validation.

Unlike fragmented in-house databases or instrument-specific solutions, these APIs offer a continuously curated, vendor-neutral foundation that supports multi-technique workflows, regulatory compliance, and cross-platform interoperability. As a result, laboratories can increase throughput, minimize downtime, and protect the value of the instrumentation and data in which they've already invested.

Spectral Databases & APIs

Spectral databases contain unique molecular “fingerprints” of substances captured through analytical techniques such as infrared (IR), mass spectrometry (MS), nuclear magnetic resonance (NMR), and Raman spectroscopy. By comparing experimental spectra against validated reference data, researchers can accurately identify unknown compounds across a wide range of applications.

An API is a common way for computer systems, from lab instruments to software platforms, to request information from one another and get an answer back automatically.

For more information about the Wiley spectral analysis API portfolio

Click Here

Company

Logo:

Wiley-VCH

Boschstrasse 12
69469 Weinheim
Germany

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.